Increased IOP Causes Astrocytes to Digest the Optic Nerve
The authors found that increased IOP caused astrocytes outside the myelin transition zone to become phacocytic through increased Mac-2 expression. This provides a plausible mechanism by which glaucomatous damage could begin during a patient's lifetime and would fit with our knowledge that lowering IOP with medication/surgery is an effective way to reduce glaucomatous progression. Remarkably, this change in gene expression was specific to pressure increase and did not occur with other manipulations of the nerve (eg, optic nerve crush).
Genetic Variation in Astrocyte Phagocytosis due to Gamma Synuclein
These results suggest that failure to clear axon-derived material (one of them being gamma synuclein) at the myelin transition zone may contribute to axonal loss in glaucoma. The findings indicate that there are proteaseresistant forms of gamma synuclein in glaucoma that are similar to Parkinson disease. There are different types and amounts of gamma synuclein; the DBA/2J glaucoma mouse model has a large amount of digestion-resistant gamma synuclein when compared with control mice.
Discovering the genetic and molecular triggers for glaucomatous damage has inherent appeal. The ability to modulate these triggers could lead to a very effective new class of medications that would treat the neuronal damage itself instead of a risk factor. 
*

Brimonidine Does Not Lower IOP at Night
The authors showed that brimonidine monotherapy lowered IOP effectively during daytime hours but not during the night. The study recruited 40-to 70-year-old, newly diagnosed, untreated glaucoma or ocular hypertensive patients. Each patient received baseline 24-hour IOP measurements followed by a second 24-hour series after 1 month of treatment with brimonidine three times a day. Interestingly, this reduction in IOP after treatment could
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be observed even when it was measured while patients were in the supine position during the day, showing that simple postural changes were not responsible. Heart rate, mean arterial pressure, and ocular perfusion pressure were measured before and after brimonidine treatment to ensure that topical brimonidine treatment did not affect these cardiovascular factors. In addition, the study was administered under strict laboratory conditions, with regulated hours of light and dark and monitored administration of eye drops at set 8-hour intervals.
Use Brimonidine Only Before Breakfast and Lunch
The authors stated that there is a plausible physiological rationale to explain the daytime-only IOPreducing effects of brimonidine as well as ß-blockers. Both classes of drugs act to suppress the endogenous ß-adrenergic stimulus to produce aqueous that is only present during the daytime. Blocking this signal when it is not present, whether at the presynaptic α2 receptor or at the postsynaptic ß receptor, does not lead to an appreciable change. It remains unknown why increases in uveoscleral outflow were not appreciable at night with brimonidine therapy as opposed to prostaglandin agonist therapy. The authors pointed out that, because brimonidine does not lower IOP during nighttime hours, the third dose of brimonidine taken at bedtime is unnecessary, adds to the cost, and reduces rates of compliance. 
*
Brimonidine but Not Timolol Prevents Progression in Low-Pressure Glaucoma
Patients with low-pressure glaucoma were randomly assigned to twice-daily monotherapy with either brimonidine tartrate 0.2% or timolol maleate 0.5%. They were observed for 4 years to detect visual field progression shown by a decrease of greater than 1 dB per year in the same three or more points shown on three consecutive tests. Subjects and physicians were blind to the medication assigned. Subjects were assigned in blocks of seven such that four patients received brimonidine and three received timolol, since the discontinuation rate for brimonidine is generally greater than that for timolol. Ninety-nine patients were randomized to brimonidine, and 79 were randomized to timolol.
Significantly fewer subjects treated with brimonidine (nine subjects, 9.1%) were found to have progressed than those treated with timolol (31 subjects, 28.3%) at the endpoint of the study, despite similar IOP values at all time points. A greater percentage of subjects assigned to brimonidine (28 subjects, 28.3%) withdrew from the study than patients assigned to timolol (nine subjects, 11.4%). The most common reason for withdrawal was localized ocular allergy, which occurred in 20 patients using brimonidine and three patients using timolol. Careful analyses were performed to ensure that there was no significant difference in the patients who discontinued treatment as opposed to subjects who remained in the study to ensure that the difference seen between treatment groups was not due to self-selection bias.
Brimonidine Neuroprotection or Damaging Reduction of Perfusion With Timolol?
Since brimonidine and timolol have very similar IOPlowering profiles, this study provides an opportunity to evaluate the potential neuroprotective properties of the former. A little-known fact is that ß-adrenergic receptor blockage (timolol) and α2 adrenergic receptor stimulation (brimonidine) have the same intracellular cascade, because both cause a downregulation of adenylate cyclase with decreased cyclic adenosine monophosphate. The fewer progressors in the brimonidine group could be due to protection conferred by brimonidine, a risk conferred by timolol, or some combination of the two.
A lowering in heart rate or blood pressure by timolol is one potential source of the greater progression amongst timolol recipients. A recent study by Quaranta et al, however, showed that treatment with brimonidine caused a greater decrease in these parameters than treatment with timolol. 6 Pressure differences not captured during office visits are another potential source of this difference. Liu 
